Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price was up 3% during trading on Friday . The company traded as high as $26.74 and last traded at $26.74, with a volume of 291,619 shares. The stock had previously closed at $25.96.

A number of equities analysts recently commented on TBPH shares. Leerink Swann reaffirmed a “buy” rating and set a $31.00 price target on shares of Theravance Biopharma in a research note on Tuesday. Guggenheim initiated coverage on shares of Theravance Biopharma in a report on Monday, June 20th. They set a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Tuesday, July 12th. Finally, Bank of America Corp. lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Theravance Biopharma presently has a consensus rating of “Hold” and an average price target of $29.00.

The firm’s 50 day moving average price is $23.89 and its 200 day moving average price is $20.56. The company’s market capitalization is $1.20 billion.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Equities research analysts forecast that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.